MOF-Based unit foR genErATing Hospital-gradE oxygen (BREATHE)

随着英国新冠肺炎感染率的飙升，需要住院治疗的患者数量也成比例增加。不幸的是，目前还没有针对新冠肺炎的有效靶向治疗方法，然而，已有证据表明，高流量氧气可以提高患者的生存机会。不出所料，医院和家庭护理治疗的氧气需求在过去12个月里大幅增加了33%，预计还将继续增长，因为COVID病例的数量预计将在未来几个月进一步增加。为了满足这一增长的需求，并确保医院和医生有足够的按需氧气容量来治疗英国人口，呼吸公司将开发新一代节能氧气浓缩器，使其能够生产更高纯度的氧气。MOF Technologies是金属有机骨架(MOF)制造和商业化方面的世界领先公司。MOF技术公司将利用其产品开发专业知识开发第一台基于MOF的氧气发生器。通过开发一种氧气浓缩器，提高氧气纯度，同时降低单位尺寸和运行成本，呼吸将提供改善医疗部门按需氧气生产的能力。呼吸将采用名为MOFS的新一代吸附剂，以获得无与伦比的空气分离效率，并提高氧气纯度。呼吸将增加能够获得医用级氧气的患者数量，在这些关键时刻加强英国的医疗保健系统。

As COVID-19 infection rates soar across the UK, the number of patients requiring hospital treatment increases proportionally. Unfortunately, there is not yet a targeted effective cure for COVID-19, however, it has been demonstrated that high-flow oxygen improves a patient's chances of survival. Unsurprisingly, the oxygen demand for hospital and home care treatment has significantly increased by 33% in the last 12 months and it is envisaged to continue growing, as the number of COVID cases is expected to further increase in the upcoming months.To meet this increased demand and ensure hospitals and doctors have enough on-demand oxygen capacity to treat the UK population, BREATHE will develop a new generation of energy-efficient oxygen concentrators that enable the production of greater oxygen purity.MOF Technologies is the world-leading company in the manufacturing and commercialisation of metal-organic frameworks (MOFs). MOF Technologies will exploit its product development expertise to develop the first MOF-based oxygen generator. BREATHE will provide improve the on-demand oxygen production in the medical sector by developing an oxygen concentrator with boosted oxygen purity while reducing both unit size and running costs. BREATHE will incorporate a new generation of adsorbents called MOFs to obtain an unsurpassed air separation efficiency and boost O2 purity. BREATHE will increase the number of patients that can have access to medical-grade oxygen, strengthening the UK health care system in these crucial times.